Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 52-68, January 2009

Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy

  • Krishna K. Gaddam, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Krishna K. Gaddam, MD, 115 Community Health Services Building, 933 19th Street South, Birmingham, Alabama 35294. Tel: 205-934-9281; fax: 205-934-1302
    • ,
  • Suzanne Oparil, MD

Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama, USA

Received 3 December 2007; accepted 28 June 2008. published online 15 September 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Dr. Gaddam is a postdoctoral fellow supported by Grant NHLBI T32 HL007457. Dr. Oparil is the recipient of Grants-in-Aid from Abbott Laboratories, Astra Zeneca, Aventis, Biovail, Boehringer Ingelheim, Bristol Myers-Squibb, Forest Laboratories, GlaxoSmithKline, Novartis, Merck & Co, Pfizer, Daiichi-Sankyo Pharma, Sanofi-Aventis, and Schering-Plough. Dr. Oparil is a consultant for Bristol-Myers Squibb, Daiichi-Sankyo, Merck & Co., Novartis, Pfizer, Sanofi Aventis, and The Salt Institute.

PII: S1933-1711(08)00140-X

doi:10.1016/j.jash.2008.06.004

Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 52-68, January 2009

Article Tools

* Image Usage & Resolution